

Press release December 3, 2009

The board of directors of Biovitrum utilizes authorization to repurchase shares to secure the company's performance based, long-term share program for 2009

The Annual General Meeting of Biovitrum resolved on 28 April 2009 to issue 231,585 series C shares to secure that the company can fulfill its commitment according to the performance based, long-term share program for 2009 ("Share Program 2009"). Furthermore, the Annual General Meeting resolved to authorize the board of directors to repurchase all issued series C shares for a price per share corresponding to the quota value of the Biovitrum share, i.e. in total SEK 127,069.9623. The series C shares will thereafter be converted to common shares in the number that is required to secure delivery under the Share Program 2009.

The board of directors of Biovitrum has resolved to utilize the authorization for this purpose and to immediately repurchase all issued series C shares in accordance with the resolution by the Annual General Meeting on 28 April 2009. Biovitrum currently holds 284,000 own series C shares which were issued during 2008.

For further information, please contact:

Biovitrum AB (publ)

Martin Nicklasson, CEO
Phone: +46 8 697 20 00

Göran Arvidson, CFO
Phone: +46 70 633 30 42

Erik Kinnman, VP Investor Relations
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com

About Biovitrum

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. Biovitrum has revenues of approximately SEK 1.2 billion and approximately 400 employees (prior to the Transaction). Biovitrum's head office is located in Sweden and the share is listed on the NASDAQ OMX Stockholm. For more information please visit www.biovitrum.com.

The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 8:30 CET on December 3, 2009.